Multiple rising doses of oral BI 1358894 in healthy male volunteers: a phase I study investigating safety, tolerability and pharmacokinetics

被引：3
|
作者：
Goettel, M. [1 ]
Fuertig, R. [2 ]
Wiebe, S. [2 ]
Herich, L. [3 ]
Sharma, V. [4 ]
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Global Clin Operat, Ingelheim, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Translat Med & Clin Pharmacol, Biberach, Germany
[3] Staburo GmbH, Munich, Germany
[4] Boehringer Ingelheim Pharma GmbH & Co KG, TA CNS Retinopathies Emerging Areas Med, Ingelheim, Germany
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2020年 / 40卷
关键词：
D O I：
10.1016/j.euroneuro.2020.09.330
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.447
引用
收藏
页码：S254 / S255
页数：2
相关论文
共 50 条
  • [1] Multiple Rising Doses of Oral BI 1358894 in Healthy Male Volunteers: A Phase I Study to Investigate Safety and Tolerability
    Goettel, Markus
    Herich, Lena
    Wiebe, Sabrina
    Fuertig, Rene
    Sharma, Vikas
    Goettel, Markus
    BIOLOGICAL PSYCHIATRY, 2020, 87 (09) : S417 - S418
  • [2] Safety, Tolerability, and Pharmacokinetics of Oral BI 1358894 in Healthy Japanese Male Volunteers
    Yoon, Jangsoo
    Sharma, Vikas
    Harada, Akiko
    CLINICAL DRUG INVESTIGATION, 2024, 44 (05) : 319 - 328
  • [3] A phase I single-rising-dose study of oral BI 1358894 in healthy male volunteers: safety, pharmacokinetics and food effect
    Fuertig, R.
    Goettel, M.
    Hoefler, J.
    Sharma, V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S256 - S257
  • [4] Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies
    René Fuertig
    Markus Goettel
    Lena Herich
    Josef Hoefler
    Sabrina T. Wiebe
    Vikas Sharma
    CNS Drugs, 2023, 37 : 1081 - 1097
  • [5] Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies
    Fuertig, Rene
    Goettel, Markus
    Herich, Lena
    Hoefler, Josef
    Wiebe, Sabrina T.
    Sharma, Vikas
    CNS DRUGS, 2023, 37 (12) : 1081 - 1097
  • [6] First-In-Human Study of Oral BI 1358894 in Healthy Male Volunteers: A Phase I Study to Investigate Safety and Tolerability
    Goettel, Markus
    Hoefler, Josef
    Fuertig, Rene
    Sharma, Vikas
    Goettel, Markus
    BIOLOGICAL PSYCHIATRY, 2020, 87 (09) : S289 - S290
  • [7] Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of Bi 1569912 in Healthy Males: A Phase I Study
    Desch, Michael
    Huennemeyer, Andreas
    Suessmuth, Sigurd D.
    BIOLOGICAL PSYCHIATRY, 2022, 91 (09) : S379 - S379
  • [8] A PHASE I STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE AND MULTIPLE DOSES OF SUBLINGUALLY ADMINISTERED ASENAPINE IN HEALTHY MALE VOLUNTEERS
    Dogterom, P.
    Timmer, C.
    de Greef, R.
    Spaans, E.
    de Vries, D.
    Peeters, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S86 - S87
  • [9] A phase I single-rising dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral akt inhibitor in healthy male volunteers
    Trucksis, Michele
    Friedman, Evan
    Taylor, Adekemi
    Delgado, Liliana
    Reynders, Tom
    DeSmet, Marina
    Dong, Yingwen
    Fu, Irong
    DeMeyer, Igance
    Chodakewitz, Jeffrey
    Iwamoto, Marian
    Wagner, John
    CANCER RESEARCH, 2009, 69
  • [10] Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics
    Moschetti, Viktoria
    Schlecker, Christina
    Wind, Sven
    Goetz, Sophia
    Schmitt, Holger
    Schultz, Armin
    Liesenfeld, Karl-Heinz
    Wunderlich, Glen
    Desch, Michael
    CLINICAL DRUG INVESTIGATION, 2018, 38 (08) : 737 - 750
12345